BioLineRx Initiates Phase 2b Clinical Trials Of BL-1020, A GABA-Enhanced Antipsychotic For The Treatment Of Schizophrenia

BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced the initiation of a Phase 2b clinical trial to assess the efficacy, safety and tolerability of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. In this six-week, double-blind, parallel group study, patients will be randomized to one of four arms, receiving a low dose or high dose of BL-1020; risperidone, an approved atypical schizophrenia drug; or placebo.

More: continued here

Filed under: Schizophrenia on June 19th, 2008